BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31197828)

  • 1. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
    Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer.
    Shinto E; Omata J; Sikina A; Sekizawa A; Kajiwara Y; Hayashi K; Hashiguchi Y; Hase K; Ueno H
    BJS Open; 2020 Apr; 4(2):301-309. PubMed ID: 32026629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
    Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
    Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
    Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
    Kitagawa Y; Akiyoshi T; Yamamoto N; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Fukunaga Y; Hirota T; Noda T; Kawachi H
    Clin Colorectal Cancer; 2022 Mar; 21(1):e1-e11. PubMed ID: 35123891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.
    McCoy MJ; Hemmings C; Anyaegbu CC; Austin SJ; Lee-Pullen TF; Miller TJ; Bulsara MK; Zeps N; Nowak AK; Lake RA; Platell CF
    Oncotarget; 2017 Mar; 8(12):19803-19813. PubMed ID: 28177891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
    Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
    Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Inflammatory Markers Combined with Tumor-Infiltrating Lymphocyte Density for the Improved Prediction of Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.
    Sawada R; Akiyoshi T; Kitagawa Y; Hiyoshi Y; Mukai T; Nagasaki T; Yamaguchi T; Konishi T; Yamamoto N; Ueno M; Fukunaga Y
    Ann Surg Oncol; 2021 Oct; 28(11):6189-6198. PubMed ID: 33876358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
    Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell complexity and density are associated with sensitivity to neoadjuvant chemoradiotherapy in patients with rectal cancer.
    Akiyoshi T; Gotoh O; Tanaka N; Kiyotani K; Yamamoto N; Ueno M; Fukunaga Y; Mori S
    Cancer Immunol Immunother; 2021 Feb; 70(2):509-518. PubMed ID: 32845355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
    Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
    Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma.
    Goedegebuure RSA; Harrasser M; de Klerk LK; van Schooten TS; van Grieken NCT; Eken M; Grifhorst MS; Pocorni N; Jordanova ES; van Berge Henegouwen MI; Pouw RE; Verheul HMW; van der Vliet JJ; van Laarhoven HWM; Thijssen VLJL; Bass AJ; De Gruijl TD; Derks S
    Oncoimmunology; 2021; 10(1):1954807. PubMed ID: 34377591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.
    Seierstad T; Hole KH; Grøholt KK; Dueland S; Ree AH; Flatmark K; Redalen KR
    Br J Radiol; 2015 Jul; 88(1051):20150097. PubMed ID: 25899892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
    Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
    Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral Budding and CD8-Positive T-cell Density in Pretreatment Biopsies as a Predictor of Response to Neoadjuvant Chemoradiotherapy in Advanced Rectal Cancer.
    Sano S; Akiyoshi T; Yamamoto N; Hiyoshi Y; Mukai T; Yamaguchi T; Nagasaki T; Taketomi A; Fukunaga Y; Kawachi H
    Clin Colorectal Cancer; 2023 Dec; 22(4):411-420.e1. PubMed ID: 37516615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
    Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
    Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.